The effect of spray drying solvent on in vitro deposition profiles and pulmonary absorption of rifampicin microparticles

Journal of Drug Delivery Science and Technology

Volumn 18, Issue 3, 2008, Pages 203-208

  Darbandi, M ^a   Gilani, K ^a   Rouholamini Najafabadi, A ^a   Barghi, M ^b   Tajerzadeh, H ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Aerodynamic behavior; Dry powder inhaler (DPI); Pulmonary absorption; Rifampicin

Indexed keywords

DICHLOROMETHANE; HELIUM; RIFAMPICIN; SOLVENT; WATER;

ABSORPTION; AEROSOL; AQUEOUS SOLUTION; BLOOD LEVEL; DIFFERENTIAL SCANNING CALORIMETRY; HALF LIFE TIME; IN VITRO STUDY; INFRARED SPECTROSCOPY; LASER DIFFRACTION; MAXIMUM PLASMA CONCENTRATION; PARAMETERS; PHARMACOKINETICS; POWDER INHALER; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; THERMOGRAVIMETRY; X RAY DIFFRACTION;

EID: 50949122494     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(08)50037-2     Document Type: Article

References (40)

1. nd edition, CRC Press, Boca Raton, Florida, 2001, pp. 19-48.
2. Dye C., Scheeie S., Dolin P., Pathania V., Raviglion M. C. - Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country, World Health Organization Global Surveillance and Monitoring Project. - JAMA., 282, 677-686, 1999.
3. Amadottir T. - Tuberculosis: trends and the twenty-first century. - Scand. J. Infect. Dis., 33, 563-567, 2001.
4. Addington W. W. - Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. - Chest., 76, 741-743, 1979.
5. Schaberg T. - The dark side of ant tuberculosis therapy: adverse events involving liver function. - Eur. Respir. J., 8, 1247-1249, 1995.
6. Davidson P. T., Le H. Q. - Drug treatment of tuberculosis. - Drugs, 43, 651-673, 1992.
7. Singh S., Mariappan T. T., Sankar R., Sarda N., Singh B. - Acritical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercularfixed-dose combination (FDC) products, and the likely solution to the problem. - Int. J. Pharm., 228, 5-17, 2001. (Pubitemid 32905361)
8. Henwood S. Q., Liebenberg W., Tiedt L. R., Lotter A. P., Villiers M. M. - Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. - Drug. Dev. Ind. Pharm., 27, 1017-1030, 2001. (Pubitemid 34053197)
9. Shishoo G. J., Shah S. A., Rathod I. S., Salvale S. S., Vora M. J. - Impaired bioavailability of rifampicin in presence of INH from fixed dose combination (FDC) formulation. - Int. J. Pharm., 228, 53-67, 2001. (Pubitemid 32905365)
10. Kohno H. B., Hata T., Tsuchiya H., Kubo K., Yacugak Z. - Enzyme induction of rifampicin and its time dependent pharmacokinetics. - J. Pharmacol. Soc. Japan, 14, 884-895, 1984.
11. Barrow E. L, Winchester G. A., Staas J. K., Quenelle D. C., Barrow W. W. - Use of microsphere technology for targeted delivery of rifampin to mycobacterium tuberculosis-infected macrophages. - Antimicrob. Agents. Chemother., 42, 2682-2689, 1998. (Pubitemid 28462915)
12. Ahsan F., Rivas I. P., Khan M. A., Torres Suares A. I. - Targeting to macrophages: role of physicochemical properties of particulate carrier-liposome's and microspheres on the phagocytosis by macrophages. - J. Contempt. Relig., 79, 431-434, 2002.
13. Makino K., Nakajima T., Shikamura M., Ito F., Ando S., Cochi C, Inagawa H., Soma G., Terada H. - Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin loaded PLGA microspheres: effect of molecular weight and composition of PLGA on release of rifampicin. - Colloids. Surf. Biointerphase, 36, 35-42, 2004. (Pubitemid 38829328)
14. Suarez S., Ohara P., Kazantseva M., Newcomer C. E., Hopfer R., Mcmurray D. N., Hickey A. J. - Airways delivery of rifampicin microparticles for the treatment of the tuberculosis. - J. Antimicrob. Chemother., 48, 431-434, 2001. (Pubitemid 32898818)
15. Pandey R., Sharma A., Zahoor A., Sharma S., Khuler G. K., Prasad B. - Poly (DL-Lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. - J. Antimicrob. Chemother., 52, 981-986, 2003. (Pubitemid 38008419)
16. Zeng X. M., Martin G. P., Marriott C. - Particle Interaction in Dry Powder Formulations for Inhalations. - Taylor and Francis, London, 2001.
17. Prime D., Atkins P J., Slater A., Sumby B. - Review of dry powder inhalers. - Adv. Drug. Del. Rev., 26, 51-58, 1997. (Pubitemid 27288484)
18. Steckel H., Rasenack N., Mullert B. W. - In situ micronization of disodium cromoglycate for pulmonary delivery. - Eur. J. Pharm. Biopharm., 55, 173-180, 2003. (Pubitemid 36299214)
19. Najafabadi Ar., Vatanara A., Gilani K., Rafiee-Tehrani M. - Formation of salbutamol sulphate microparticles using solution enhanced dispersion by supercritical carbon dioxide. - Dam., 13, 1-5, 2005. (Pubitemid 41557098)
20. Najafabadi Ar., Gilani K., Barghi M., Rafiee-Tehrani M. - The effect of vehicle on physical properties and aerosolisation behavior of disodium cromoglycate microparticles spray dried alone or with L-Leucine. - Int. J. Pharm., 296, 26-33, 2004.
21. Dellamary L. A., Tarara T. E., Smith D. J., Woelk C. H., Adractas A., Costello M. L., Gill H., Weers J. G. - Hollow porous particles in metered dose inhalers. - Pharm. Res., 17, 168-174, 2000. (Pubitemid 30158365)
22. Hickey A. J., Martonen T. B., Yang Y. - Theoretical relation ship of lung deposition to the fine particle fraction of inhalation aerosols. - Pharm. Acta. Helv., 71, 185-190, 1996. (Pubitemid 26290616)
23. Hooton J. C., Jones M. D., Price R. - Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach. - J. Pharm. Sci., 95 (6) 1288-1297, 2006. (Pubitemid 43874442)
24. Enna Sj., Schanker L. S. - Absorption of saccharides and urea from the rat lung. - Am. J. Physiol., 222, 409-414, 1972.
25. Saito H., Tomioka H. - Therapeutic efficacy of liposome-entrapped rifampin against mycobacterium avium complex infection induced in mice. - Antimicrobial. Agent. Chemoter., 33, 429-433, 1989. (Pubitemid 19094267)
26. Gadret P. M., Goursolle M., Leger J. M., Colleter C. - Structure cristalline de la rifampicine C43N4O12H55.5H2O. - Acta Cryst., B31, 1454-1462, 1975.
27. Gallo G. G., Radaelli P. - Rifampicin in analytical profile of drug substance, Florey K. Ed, Academic Press, New York, 5, 1976, pp. 467-513.
28. Pelizza G., Nebuloni M., Ferrari P., Gallo G. G. - Polymorphism of rifampicin. - II Farmaco., 32, 471-481, 1977. (Pubitemid 8158645)
29. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. - Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlucast hydrate. - Int. J. Pharm., 172, 178-188, 1998.
30. Steckel H., Markefka P., Tewierika H., Kammellar R. - Effect of milling and sieving on functionality of dry powder inhalation products. - Int. J. Pharm., 309, 51-59, 2006. (Pubitemid 43129464)
31. Giry K., Pean J. M., Girand L, Marsas S., Rolland H., Wuthrich P. - Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation. - Int. J. Pharm., 321, 162-166, 2006. (Pubitemid 44247415)
32. Podezeck F. - Evaluation of the adhesion properties of salbutamol sulphate to inhaler materials. - Parm. Res., 15, 806-808, 1998.
33. Lida K., Otsuka A., Danjo K., Sunada H. - Measurement of adhesive force between particles and polymer-film. - Chem. Pharm. Bull, 40, 189-192, 1992.
34. Shimada Y., Yonezawa Y., Sunada H. - Measurement and evaluation of the adhesive force between particles by the direct separation method. - J. Pharm. Sci, 92, 560-568, 2003. (Pubitemid 36258970)
35. Nicklin P. L., Bayley D., Giddlings J., Craig S. J., Cummins L. L., Hastwell J. G., Philips J. A. - Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP-64128A): comparison with other delivery routs. - Pharm. Res., 15, 583-591, 1998. (Pubitemid 28214952)
36. Ogura T., Furuya Y., Matsuura S. - HPMC capsule an alternative to gelatin. - Pharm. Technol. Eur., 10, 32-42, 1998.
37. Kassem N. M., Shamat M. A., Duval C. - The inspirable properties of a carrier-free dry powder aerosol formulation. - J. Pharm. Pharmacol., 43, 75 p., 1991.
38. Enna Sj., Schanker L. S. - Absorption of drugs from the rat lung. - Am. J. Physiol., 223, 1227-1231, 1972.
39. Aracawa E., Kitazawa S. - Studies on the factors affecting pulmonary absorption of xanthine derivatives in the rat. - Chem. Pharm. Bull., 35, 2038-2044, 1987.
40. Ohtani T., Murakami M., Yamamoto A., Takada K., Muranishi S. - Effect of absorption enhancers on pulmonary absorption of fluorescein isothiocyanate dextrans with various molecular weights. - Int. J. Pharm., 77, 141-150, 1991.